penpulimab + gemcitabine + cisplatin

Penpulimab + gemcitabine + cisplatin is a **combination regimen** used in the treatment of various advanced solid tumors, including metastatic pancreatic cancer and other upper gastrointestinal cancers. **Penpulimab** is a humanized monoclonal antibody targeting **Programmed death protein-1 (PD-1)**, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor response. **Gemcitabine** is a nucleoside analog and **antineoplastic agent** that inhibits DNA synthesis, while **cisplatin** is a platinum-based chemotherapy agent causing crosslinking of DNA, leading to apoptosis in cancer cells. This combination leverages immunotherapy with cytotoxic chemotherapy for a synergistic effect in tumor control and is under investigation in first-line settings for metastatic cancer[1][2][3][6].